umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Genetic variation in the upstream region of ERG and prostate cancer.
Umeå University, Faculty of Medicine, Department of Radiation Sciences, Oncology. (Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden)
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. (Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA)
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Show others and affiliations
2009 (English)In: Cancer Causes and Control, ISSN 0957-5243, E-ISSN 1573-7225, Vol. 20, no 7, 1173-1180 p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: A considerable fraction of prostate cancers harbor a gene fusion between the androgen-regulated TMPRSS2 and ERG, one of the most frequently over-expressed proto-oncogenes in prostate cancer. Here, we investigated if inherited genetic variation upstream of ERG alters prostate cancer risk and survival. METHODS: We genotyped 21 haplotype tagging SNPs (htSNPs) covering 123 kb of 5'UTR DNA including exon 3 of ERG in 2,760 incident prostate cancer cases and 1,647 controls from a population-based Swedish case-control study (CAPS). Individual SNPs and haplotypes were tested for association with prostate cancer risk and survival. RESULTS: One haplotype-'CTCGTATG' located 100 kb upstream of ERG-was associated with lethal prostate cancer (HR, 1.36; 95% CI, 1.2-1.9, p = 0.006). Carriers of the variant 'T' allele of rs2836626 were diagnosed with higher TNM-stage (p = 0.009) and had an increased risk of prostate cancer-specific death (HR = 1.3; 95% CI, 1.1-1.7, p = 0.009). However, this association did not remain statistically significant after adjusting for multiple testing. We found overall no association between ERG variation and prostate cancer risk. CONCLUSIONS: Genetic variation upstream of ERG may alter prostate cancer stage and ultimately prostate cancer-specific death but it is unlikely that it plays a role in prostate cancer development.

Place, publisher, year, edition, pages
2009. Vol. 20, no 7, 1173-1180 p.
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-25816DOI: 10.1007/s10552-009-9305-3PubMedID: 19205910OAI: oai:DiVA.org:umu-25816DiVA: diva2:233977
Available from: 2009-09-03 Created: 2009-09-03 Last updated: 2017-12-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lindström, SaraStattin, Pär
By organisation
OncologyUrology and Andrology
In the same journal
Cancer Causes and Control
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 24 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf